Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial

International Journal of Cardiology

Volumn 170, Issue 2, 2013, Pages 215-220

  Bahit, Maria Cecilia ^a   Lopes, Renato D ^b   Wojdyla, Daniel M ^b   Hohnloser, Stefan H ^c   Alexander, John H ^b   Lewis, Basil S ^d   Aylward, Philip E ^e   Verheugt, Freek W A ^f   Keltai, Matyas ^g   Diaz, Rafael ^a   Hanna, Michael ^h   Granger, Christopher B ^b   Wallentin, Lars ⁱ  

^a Etudios Cardiologica Latin America Rosario   (Argentina)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d CARMEL MEDICAL CENTER   (Israel)

^e FLINDERS UNIVERSITY   (Australia)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g SEMMELWEIS UNIVERSITY   (Hungary)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ UPPSALA UNIVERSITY   (Sweden)

Author keywords

Apixaban; Atrial fibrillation; Coronary artery disease; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; PLACEBO; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC DISEASE; TREATMENT OUTCOME;

APIXABAN; ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; WARFARIN;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; EMBOLISM; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84889091872     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.10.062     Document Type: Article

References (35)

1. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
2. S. Stewart, C.L. Hart, D.J. Hole, and J.J. McMurray A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study Am J Med 113 2002 359 364
3. W.B. Kannel, R.D. Abbott, D.D. Savage, and P.M. McNamara Epidemiologic features of chronic atrial fibrillation: the Framingham study N Engl J Med 306 1982 1018 1022
4. K.G. Peters, and M.G. Kienzle Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm Am J Med 85 1988 242 244
5. A. Ott, M.M. Breteler, M.C. de Bruyne, F. van Harskamp, D.E. Grobbee, and A. Hofman Atrial fibrillation and dementia in a population-based study. The Rotterdam Study Stroke 28 1997 316 321
6. D.E. Singer, Y. Chang, and M.C. Fang The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Intern Med 151 2009 297 305
7. S. Goto, D.L. Bhatt, and J. Röther Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis Am Heart J 156 2008 855 863 [863 e2]
8. M.B. Rothberg, C. Celestin, L.D. Fiore, E. Lawler, and J.R. Cook Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit Ann Intern Med 143 2005 241 250
9. U. Stenestrand, J. Lindback, and L. Wallentin Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) Circulation 112 2005 3225 3231
10. R.D. Lopes, A. Starr, and C.F. Pieper Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes Am J Med 123 2010 134 140
11. M.D. Ezekowitz, S. Connolly, and A. Parekh Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran Am Heart J 157 2009 805 810
12. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
13. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study Am Heart J 159 2010 340 347
14. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
15. R.D. Lopes, J.H. Alexander, and S.M. Al-Khatib Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
16. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
17. S.H. Hohnloser, J. Oldgren, and S. Yang Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial Circulation 125 2012 669 676
18. S.J. Connolly, J. Eikelboom, and C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
19. J.H. Alexander, R.D. Lopes, and S. James Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
20. J.L. Mega, E. Braunwald, and S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
21. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
22. D.Y. Lin, L.J. Wei, and Z. Ying Checking the Cox model with cumulative sums of martingale-based residuals Biometrika 80 1993 557 572
23. L. Friberg, M. Rosenqvist, and G.Y. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study Circulation 125 2012 2298 2307
24. C. van Walraven, R.G. Hart, and D.E. Singer Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis JAMA 288 2002 2441 2448
25. V.L. Baczek, W.T. Chen, J. Kluger, and C.I. Coleman Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis BMC Fam Pract 13 2012 5
26. D.J. Gladstone, E. Bui, and J. Fang Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated Stroke 40 2009 235 240
27. D.P. Faxon, J.W. Eikelboom, and P.B. Berger Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective Thromb Haemost 106 2011 572 584
28. J.J. You, D.E. Singer, and P.A. Howard Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e531S e575S
29. G.Y. Lip, K. Huber, and F. Andreotti Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting Thromb Haemost 103 2010 13 28
30. W.J. Dewilde, T. Oirbans, and F.W. Verheugt Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
31. J.H. Alexander, R.D. Lopes, and J.J.V. McMurray Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in patients taking concomitant aspirin Poster presented at: 2012 American College of Cardiology Annual Scientific Session; March 25, 2012; Chicago, IL 2012
32. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 2012 397 402
33. J.L. Mega, E. Braunwald, and S.A. Murphy Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial J Am Coll Cardiol 61 2013 1853 1859
34. D. Garcia, E. Libby, and M.A. Crowther The new oral anticoagulants Blood 115 2010 15 20
35. G.Y. Lip, and D.A. Lane Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 123 2010 785 789